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Abstract
Murine cytomegalovirus (MCMV) is an important animal model of human cytomegalovirus (HCMV), a b-Herpesvirus that
infects the majority of the world’s population and causes disease in neonates and immunocompromised adults. CD8
+ T cells
are a major part of the immune response to MCMV and HCMV. Processing of peptides for presentation to CD8
+ T cells may
be critically dependent on the immunoproteasome, expression of which is affected by MCMV. However, the overall
importance of the immunoproteasome in the generation of immunodominant peptides from MCMV is not known. We
therefore examined the role of the immunoproteasome in stimulation of CD8
+ T cell responses to MCMV – both
conventional memory responses and those undergoing long-term expansion or ‘‘inflation’’. We infected LMP7
2/2 and
C57BL/6 mice with MCMV or with newly-generated recombinant vaccinia viruses (rVVs) encoding the immunodominant
MCMV protein M45 in either full-length or epitope-only minigene form. We analysed CD8
+ T cell responses using
intracellular cytokine stain (ICS) and MHC Class I tetramer staining for a panel of MCMV-derived epitopes. We showed a
critical role for immunoproteasome in MCMV affecting all epitopes studied. Interestingly we found that memory ‘‘inflating’’
epitopes demonstrate reduced immunoproteasome dependence compared to non-inflating epitopes. M45-specific
responses induced by rVVs remain immunoproteasome-dependent. These results help to define a critical restriction point
for CD8
+ T cell epitopes in natural cytomegalovirus (CMV) infection and potentially in vaccine strategies against this and
other viruses.
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Introduction
Human cytomegalovirus (HCMV) is a b-Herpesvirus, a double-
stranded DNA virus encoding 160 proteins, which infects most of
the world’s population [1]. Infection is asymptomatic in immuno-
competent hosts; however, virus is not cleared after acute infection
and persists lifelong. In immunocompromised hosts, such as those
infected with HIV and bone marrow transplant (BMT) recipients,
HCMV infection may cause severe disease. Murine cytomegalo-
virus (MCMV) is a well-characterized animal model for HCMV,
reflecting many key aspects of the immunology of human infection
[2].
CD8
+ T cells are important mediators of immune responses to
HCMV and MCMV [3,4,5,6,7]. CD8
+ T cells in combination
with other antiviral mediators limit CMV reactivation in
immunocompetent hosts and protect against disease in immuno-
suppressed hosts. Adoptive transfer of anti-CMV CD8
+ T cells
protects from CMV-induced disease in mouse and man [8,9].
During the chronic phase of CMV infection CD8
+ T cell
responses to certain epitopes increase in number over time; this
phenomenon, called ‘memory inflation’, is characteristic of CMVs
[10,11,12,13,14]. The ‘‘superboosting’’ nature of the immune
response can be exploited in CMV-based vaccines to induce long-
term protective antiviral CD8
+ T cell responses [14,15]. However
the mechanism of memory inflation and the criteria that
distinguish those responses that inflate compared to those that
enter into a classical memory pool are not known.
The CD8
+ T cell response to virus infection is driven by the
presentation of peptide by professional antigen presenting cells
(APCs) and infected targets. Generation of the peptide repertoire
requires a series of components responsible for cleavage and
presentation [16]. The immunoproteasome is one such compo-
nent, an inducible form of the proteasome thought to be optimised
for production of MHC class I ligands [17]. All cells contain
constitutive proteasomes and respond to interferon-gamma (IFN-
c) by upregulation of immunoproteasome expression. Immune
cells, including professional APCs such as dendritic cells (DCs) and
macrophages, also constitutively express immunoproteasomes
[18,19,20].
The role of the immunoproteasome in vivo is not yet defined.
Constitutive and immuno-proteasomes produce a different profile
of potential CD8
+ T cell epitopes and epitope precursors from a
given polypeptide. In general, immunoproteasome digests contain
more potential MHC class I ligands than the constitutive
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+ T cell
epitopes are produced by both types of proteasome in cell-free
assays and by infected APCs [22]. Mice lacking functional genes
for one or two of the three catalytic subunits of the immunopro-
teasome (LMP7, LMP2 and MECL-1) produce many expected
CD8
+ T cell responses to infection, although the overall impact is
not yet clear [19,23,24,25,26]. One study of lymphocytic
choriomeningitis virus (LCMV) infection in LMP7
2/2 mice,
showed no difference in numbers of CD8
+ T cell responses or
difference in viral load and disease [27]. However, the same study
showed that in DNA vaccination with LCMV glycoprotein there is
enhanced presentation of one epitope (GP276) in the absence of
LMP7, a feature noted before in LMP7
2/2 mice when a rVV
expressing the LCMV glycoprotein was used [19]. Recently, it has
been shown that LMP7 inhibition using a small molecule inhibitor
of LMP7 strongly downregulated the CTL response to LCMV-
GP33 and NP396 (but not sub-dominant epitopes) during LCMV
infection [28]. Thus, while it is known that specific epitopes can
show immunoproteasome dependence, the overall dependence of
antiviral T cell responses on immunoproteasomes is not fully
defined.
MCMV and HCMV encode numerous immunoevasins which
affect components of the MHC class I antigen processing pathway
[29]. IFN-c-mediated upregulation of immunoproteasome expres-
sion is normally an important host response to viral infection.
However, in HCMV- or MCMV-infected cells it has been shown
that upregulation of the immunoproteasome does not occur in
response to IFN-c [30]. In murine cells this effect is mediated by
the MCMV protein M27, which prevents signaling through the
IFN-c receptor (IFNGR) by binding to the cellular signalling
intermediate STAT2 (previously thought to transduce only signals
through the interferon-a receptor (IFNAR)) [31]. It was proposed
that if the repertoire of antiviral CD8
+ T cells was selected on
constitutively immunoproteasome-rich professional APCs, such as
DCs and macrophages, they might predominantly be specific for
epitopes that are better presented by the immunoproteasome [30].
If this were true, M27-mediated suppression of immunoprotea-
some expression in infected tissue cells might protect infected cells
from detection by antiviral CD8
+ T cells.
We therefore investigated the role of the immunoproteasome in
induction of CD8
+ T cell responses to MCMV. LMP7
2/2 mice
were infected with MCMV or novel recombinant vaccinia viruses
(rVVs) expressing MCMV proteins. Antigen-specific CD8
+ T cell
responses to a panel of previously defined peptide epitopes were
quantified by ex vivo MHC class I tetramer analysis and IFN-c
intracellular cytokine stains (ICS). A key role for the immunopro-
teasome was revealed in modulating the immunodominant
response in acute disease and in a range of other epitopes. This
study reveals a major role for the immunoproteasome in
determining the CD8
+ T cell repertoire in MCMV, both in acute
infection (7 days) and chronic infection (.50 days).
Results
Responses to M45 are not detected in LMP7
2/2 mice
In wild type mice, the most dominant CD8
+ T cell response to
MCMV after acute infection (day 7) recognizes the D
b restricted
epitope M45 HGIRNASFI (hereafter described as ‘‘M45’’)
[32,33]. We aimed to determine the role of the immunoprotea-
some in induction of this response by comparing M45-specific
responses to MCMV infection in C57BL/6 mice with those in
gene-targeted knockout mice lacking a functional gene for the
immunoproteasome subunit LMP7 (LMP7
2/2) backcrossed onto
a C57BL/6 background [26]. LMP7
2/2 and C57BL/6 mice were
injected intravenously with MCMV. Seven days later, peripheral
blood or splenocytes were prepared and M45-specific responses
evaluated by tetramer stain or IFN-c ICS (Figure 1). Seven days
post-infection (p.i.) is the peak of the cellular immune responses to
MCMV and conventionally referred to as acute infection.
As expected, 4% of CD8+ T cells from the peripheral blood
stained positive with the M45 tetramer in C57BL/6 mice acutely
infected with MCMV (Figure 1A). In contrast, no M45-specific
CD8+ T cells were detected in the peripheral blood of LMP7-/-
mice. To determine whether M45-specific cells were present at
another site, splenocytes from LMP7
2/2 and C57BL/6 acutely
infected mice were stained with M45 tetramer. M45-specific
splenocytes were below the limit of detection in infected LMP7
2/2
mice (Figure 1B), compared to substantial responses (5%) detected
in C57BL/6 mice. The function of M45-specific CD8
+ T cells in
the spleens of acutely infected LMP7
2/2 mice was assessed by ex
vivo IFN-c ICS. No CD8
+ T cells from the spleens of infected
LMP7
2/2 mice produced IFN-c in response to peptide in ex vivo
IFN-c ICS (Figure 1C) compared with 1.5% of CD8
+ T cells in
MCMV-infected C57BL/6 controls.
It was possible that the pattern of responses to M45 would be
affected by the immunoproteasome in a temporal fashion (i.e.
responses may be delayed rather than absent). Using MHC class I
tetramer staining to detect M45-specific responses in the blood of
LMP7
2/2 mice up to 100 days p.i., it is apparent that the response
to M45 remained below the limit of detection at all time points
tested (Figure 1D). In comparison, in C57BL/6 mice, M45-specific
cells were maintained over time at a low level (0.4% of CD8
+ T
cells; Figure 1D).
CD8 responses to m141 are not detected in LMP7
2/2
mice
During acute MCMV infection, a second protein which
contains a highly targeted epitope in C57BL/6 mice is m141
[32]. Compared with 1.2% of CD8
+ T cells in acutely infected
C57BL/6 mice (Figure 2A), no m141-specific CD8
+ T cells were
detected in the blood of LMP7
2/2 mice at 7 days p.i. IFN-c was
not produced in response to m141 peptide by splenocytes from
infected LMP7
2/2 mice, whereas 0.5% of CD8+ T cells from
C57BL/6 mice mounted an IFN-c response to m141 peptide
(Figure 2B). In C57BL/6 mice, the number of m141-specific T
cells did not inflate over time [11]. The m141 specific responses in
the blood of LMP7
2/2 mice were examined using tetramers
between days 7 and 100 p.i. At no point in time were m141-
specific CD8+ T cells detected in the peripheral blood of
LMP7
2/2 mice (Figure 2C).
Responses to M38a and m139 are affected by LMP7
deletion
The M38 and m139 proteins of MCMV are major targets of the
CD8
+ T cell response in C57BL/6 mice. In contrast to M45 and
m141 described above, CD8
+ T cell responses to M38a and m139
both undergo memory inflation. The acute CD8
+ T cell response
to M38a is relatively small and expands only later compared to
CD8
+ T cells specific for m139, which are also relatively abundant
during the acute phase of infection [11].
Peripheral blood of MCMV-infected LMP7
2/2 and C57BL/6
mice was assayed for m139-specific CD8
+ T cells over a 100-day
time course (Figure 3A). The CD8
+ T cell response to m139 in
acute infection was reduced (0.3%) relative to the wild type
response (1.5%), but remained detectable. The difference was
greater in chronic infection; the m139-specific response in
C57BL/6 mice increased to 3.5% by 100 days p.i., whereas the
LMP7 and MCMV
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2/2 mice remained static over
time (Figure 3A). The same pattern was evident in spleens. IFN-c-
secreting m139-specific CD8
+ T cells were also detected in the
spleens of LMP7
2/2 mice 100 days p.i. by ICS (Figure 3B), but at
a lower frequency than in C57BL/6 controls (1.2% vs 2.5%;
Figure 3B).
Spleens from LMP7
2/2 and C57BL/6 mice were examined 7
and 100 days p.i. using IFN-c ICS to detect M38a-specific
CD8
+ T cells (Figure 4). During acute infection, an M38a-
specific response was not detectable in LMP7
2/2 mice
compared to a small but readily detectable response (0.4%) in
C57BL/6 mice (Figure 4A). By 100 days p.i., M38a specific
responses were easily detectable in both C57BL/6 and
LMP7
2/2 mice (Figure 4B) although smaller in LMP7
2/2
mice (2%) compared to C57BL/6 mice (5%). The increase in
frequency of M38a-specific CD8
+ T cells over time in C57BL/6
and LMP7
2/2 mice indicated that memory inflation had
occurred in both strains.
Figure 1. CD8
+ T cell responses to M45 in LMP7
2/2 mice infected with MCMV. A. LMP7
2/2 mice and C57BL/6 control mice were injected
intravenously (i.v.) with 1610
6 plaque forming units (pfu) MCMV or an equivalent volume of phosphate buffered saline (PBS). Seven days p.i.
peripheral blood was sampled by tail bleed. Whole blood was stained with fluorochrome-conjugated soluble tetrameric complexes (M45 H-2
D
b 985HGIRNASFI
993) and anti-CD8 antibody, and red blood cells lysed, before analysis by FACS. B. Lymphocytes were prepared from peripheral blood
and spleen of LMP7
2/2 and C57BL/6 control mice 7 days p.i. (n=5) or PBS treated (blood: n=2; spleen: n=4) and subjected to tetramer stain and
FACS analysis as above. The plots show the frequency of M45 D
b-specific cells among CD8
+ T cells. SEM was less than 0.1%. C. Splenocytes were
prepared from spleens of LMP7
2/2 and C57BL/6 control mice (n=5) 7 days p.i. and incubated in either media containing synthetic peptide
HGIRNASFI or media alone, in the presence of Brefeldin A (BFA). After 5 hours cells were stained for CD8 and intracellular IFN-c and analysed by FACS.
The plots show % CD8
+ T cells producing IFN-c in response to peptide or media alone. SEM was less than 0.1%. D. Peripheral blood was sampled from
LMP7
2/2 and C57BL/6 control mice (n=3) at 7, 40, 60 and 100 days p.i. and subjected to tetramer stains using M45 D
b HGIRNASFI tetramer and FACS
analysis as for Figure 1A. The plot shows the frequency of M45 D
b- specific cells among CD8
+ T cells over a 100 day time course.
doi:10.1371/journal.pone.0014646.g001
LMP7 and MCMV
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2/2 mice but at
reduced frequencies
Over 20 MCMV-derived CD8 epitopes have been defined in
C57BL/6 mice [32]. It was possible that a previously subdominant
epitope would be increased in LMP7
2/2 mice, due to altered
antigen processing or altered competition from other responses. As
described above four immunodominant responses occurred at
lower frequencies in LMP7
2/2 mice relative to C57BL/6 mice
(M45, m139, and M38a and m141). To analyze the other
responses, splenocytes from LMP7
2/2 and C57BL/6 mice, from
day 7 and .50 p.i., were exposed to a panel of synthetic peptides
corresponding to MCMV-derived CD8
+ T cell epitopes previously
defined in C57BL/6 mice (Table S1). Peptide-specific IFN-c
production by splenocytes from infected mice was assessed using
ICS. In acute infection 10 out of 11 epitopes tested that stimulated
responses in C57BL/6 mice also stimulated responses in
splenocytes from acutely infected LMP7
2/2 mice (Figure 5A).
The frequency of 9 out of 11 responses was reduced relative to the
equivalent responses in wild type mice (Figure 5A). Of the
subdominant responses, two responses, to epitopes from M78 and
M33, occurred at the same frequency in LMP7
2/2 mice as in
C57BL/6 mice, but overall these did not become immunodomi-
nant. The magnitude of all sub-dominant responses was low, close
to the value of background for the assay.
At later timepoints 5 out of 5 epitopes that stimulated responses
in C57BL/6 mice .50 days p.i. also stimulated responses in
splenocytes from chronically infected LMP7
2/2 mice (Figure 5B
and C). All responses were reduced in frequency in LMP7
2/2
mice relative to wild type responses.
The M45 response is reduced in LMP7
2/2 mice even
when M45 is expressed by rVVs
To determine whether loss of the CD8
+ T cell response to M45
in LMP7
2/2 was a quality associated with herpesvirus infection
rather than a quality of the protein required expression of M45
protein in a different viral context to that in the native herpesvirus.
Therefore, a novel rVV [34] expressing the M45 CD8
+ T cell
epitope as part of the full-length M45 protein (referred to as
M45-VV), was constructed (Figure 6A). This was used to infect
LMP7
2/2 mice and assay for CD8
+ T cell responses to M45.
C57BL/6 and LMP7
2/2 mice were injected intravenously with
M45-VV and 7 days p.i. peripheral blood was sampled. In
C57BL/6 mice, 1% of CD8
+ T cells were tetramer-positive
(Figure 6B), while in contrast, peripheral blood from LMP7
2/2
mice contained no M45-specific CD8
+ T cells as determined by
tetramer stains (Figure 6B). Thus the effect of LMP7 functional
gene deletion on response to M45 was similar in LMP7
2/2 mice
infected with MCMV or with M45-VV.
We next sought to differentiate whether either (1) loss of
immunoproteasome function or (2) a hole in the T cell repertoire
might explain why the CD8
+ T cells of LMP7
2/2 mice failed to
respond to M45 expressed from MCMV (Fig. 1) or M45-VV
(Fig. 6B) [35–36]. To address this question, a second rVV was
constructed that expressed the immunodominant 985–993 epitope
of M45 from a minigene (M45 epitope-VV; Figure 6A and Table
S2). C57BL/6 mice and LMP7
2/2 mice were intravenously
inoculated with M45 epitope-VV to determine if a CD8+ T cell
response was mounted. On day 7 p.i. 4% of peripheral blood
CD8
+ T cells in both C57BL/6 mice and LMP7
2/2 mice that
received the M45 epitope-VV were specific for the M45 tetramer.
We conclude that absence of M45-specific naı ¨ve T-cells (i.e. a hole
in the repertoire) does not explain the failure of LMP7
2/2 mice to
respond to the M45 protein when expressed from MCMV or a
Figure 2. CD8
+ T cell responses to m141 in LMP7
2/2 mice
infected with MCMV. A. Lymphocytes were prepared from peripheral
blood of LMP7
2/2 and C57BL/6 control mice 7 days p.i. (n=3) or PBS
treated (n=2) and subjected to tetramer stain and FACS analysis as for
Figure 1A, using MCMV m141 tetramer (H-2 K
b1 5 VIDASFRL
23). The plot
shows the frequency of m141 K
b-specific cells among CD8
+ T cells. B.
Splenocytes were prepared from spleens of LMP7
2/2 and C57BL/6
control mice 7 days p.i. (n=6), pooled, and incubated in the presence of
BFA with either media containing peptide VIDAFSRL or media alone for
5 hours. Cells were stained as in Figure 1C and analysed by FACS. The
plot shows % CD8
+ T cells producing IFN-c in response to peptide or
media alone. C. Peripheral blood was sampled from LMP7
2/2 andC57BL/
6 control mice (n=3) at 7, 40, 60 and 100 days p.i. and subjected to
tetramer stain and FACS analysis as for A. The plot shows the frequency
of m141 K
b-specific cells among CD8
+ T cells over a 100 day time course.
doi:10.1371/journal.pone.0014646.g002
LMP7 and MCMV
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protein compromises immunoproteasome function, which appears
to be critical if the M45 is to be proteolytically processed such that
the M45 immunodominant epitope is presented to CD8
+ T cells.
Discussion
In this study, we addressed the hypothesis that during MCMV
infection CD8
+ T cell responses specific for certain epitopes are
better processed by the immunoproteasome than the constitutive
proteasome. Immunoproteasomes and constitutive proteasomes
produce differing sets of potentially antigenic peptides during
MHC class I antigen processing for presentation to CD8
+ T cells
[21]. Professional APCs involved in priming naive CD8
+ T cells
constitutively express immunoproteasomes [18,20]. In contrast,
non-immune cells require exposure to IFN-c to upregulate
immunoproteasome expression [37]. During MCMV infection
the viral protein M27 prevents IFN-c-mediated upregulation of
immunoproteasome expression in infected cells by blocking
signaling through the IFNGR [30,31]. It was possible that M27-
mediated resistance to upregulation of immunoproteasome
expression would protect infected cells from lysis by CD8
+ T cell
responses primed with constitutively immunoproteasome-rich cells
[30]. This, however, is dependent on whether CD8
+ T cell
responses to MCMV are specific for epitopes better processed by
the immunoproteasome than the constitutive proteasome (‘‘im-
munoproteasome dependent’’).
Using MCMV infection of LMP7
2/2 mice and ex vivo CD8
+ T
cell assays for number and function, we found that the M45-
specific CD8
+ T cell response to MCMV that is immunodominant
in C57BL/6 mice is profoundly affected by loss of immunoprotea-
somes. We also observed that most other responses tested that
stimulated responses in C57BL/6 mice were reduced in LMP7
2/2
mice. Since all MCMV-derived CD8
+ T cell epitopes tested were
affected by the loss of wild-type immunoproteasome in LMP7
2/2
mice, and in studies of other viruses the effects on different
epitopes from the same virus have been divergent [22], we
speculated that the unusually consistent effect of the immunopro-
teasome was associated with herpesviral infection, and not specific
qualities of the primary sequences of the proteins from which the
epitopes were derived. Expressing the MCMV M45 (a protein
Figure 3. CD8
+ T cell response to inflating epitope m139 in LMP7
2/2 mice infected with MCMV. A. Lymphocytes were prepared from the
peripheral blood of LMP7
2/2 and C57BL/6 control mice 7 days p.i. (n=3) or PBS (n=2) and subjected to tetramer stain and FACS analysis as for
Figure 1A, using MCMV m139 tetramer (H-2 K
b 419TWYGFCLL
426). This epitope has been shown to elicit a CD8
+ T cell response that increases over
time, or inflates, in C57BL/6 mice. The plot shows the frequency of m139 K
b-specific cells among CD8
+ T cells over a 100 day time course. B.
Splenocytes were prepared from spleens of LMP7
2/2 and C57BL/6 control mice 7 days p.i. (n=3) and incubated in the presence of BFA with either
media containing synthetic peptide TWYGFCLL or media alone for 5 hours. Cells were stained for surface CD8 and intracellular IFN-c as in Figure 1C
and analysed by FACS. The plot shows % CD8
+ T cells producing IFN-c in response to peptide or media alone.
doi:10.1371/journal.pone.0014646.g003
Figure 4. CD8
+ T cell responses to inflating epitope M38 in
LMP7
2/2 mice infected with MCMV. A. Splenocytes were prepared
from spleens of LMP7
2/2 and C57BL/6 control mice 7 days p.i.(n=6),
pooled, and incubated in the presence of BFA with either media
containing peptide SSPPMFRV (M38 H-2 K
b 316SSPPMFRV
325) or media
alone for 5 hours. Cells were stained for surface CD8 and intracellular
IFN-c as in Figure 1C and analyzed by FACS. The plots show % CD8
+ T
cells producing IFN-c in response to peptide or media alone. B.
Splenocytes were prepared from spleens of LMP7
2/2 and C57BL/6
control mice 100 days p.i. (n=3) and subjected to IFN-c intracellular
cytokine stain (IFN-c ICCS) as for A.
doi:10.1371/journal.pone.0014646.g004
LMP7 and MCMV
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+ T cell epitope in C57BL/6 mice)
in the context of rVV allowed testing of this. However, no
response to M45 detectable directly ex vivo was induced in
LMP7
2/2 mice infected with rVV expressing full-length M45.
The virus induced M45-specific responses in C57BL/6 mice, and
LMP7
2/2 mice produced M45-specific CD8
+ T cell responses to
rVV expressing only the M45 minimal epitope from a minigene.
Therefore at least in the case of CD8
+ T cell response to M45 the
requirement for wild type immunoproteasome was maintained in
the absence of MCMV infection. This suggested that M45
primary sequence and not viral interference determined the effect
of the immunoproteasome on stimulation of M45-specific CD8
+ T
cell responses during MCMV infection. By extension, this suggests
that MCMV-derived CD8
+ T cell epitopes with responses reduced
in LMP7
2/2 mice might have protein primary sequences that
could be better processed by immunoproteasome. Further work
would be required to test this hypothesis more extensively;
however, if true, these would be useful data points for
immunoproteasome cleavage prediction. It should be pointed
out that LMP7 deficient mice also lack a contribution from LMP2
and MECL in immunoproteasomes [38], so it remains open which
of these subunits is actually required for the generation of the
different epitopes.
These findings have a number of implications for viral
pathogenesis. Firstly it is known that M45-specific CD8
+ T cell
populations have limited protective capacity in a bone marrow
transplant model [33,39]. This can be potentially explained by the
fact while these responses may be readily generated in LMP7
+ DCs,
for example through cross-presentation [40], the target cells
themselves, which are low in immunoproteasomes, will present
only inefficiently. Thus the relative imbalance in immunoprotea-
some distribution between APCs and target cells may have special
relevance in MCMVinfection. Other viruses where IFN-c signaling
blockade also occurs [41] might show similar phenomena.
The generalized impact of LMP7 depletion on the pattern of
CD8
+ T cell responses to MCMV epitopes was also interesting. A
number of MCMV epitopes have been mapped, although many of
the CD8
+ T cell responses are at relatively low levels compared to
the well-defined M45 response focused upon in these studies [32].
A caveat of this study is the accuracy of measurement of changes
in these very small populations. However, it is evident that a shift
in immunodominance towards these subdominant responses did
not occur. We did not in this study measure the overall impact of
LMP7 depletion on viral load over time. However, a number of
previous studies in C57BL/6 mice in which specific deletion of
CD8
+ T cells has been performed [7,42], or in CD8 gene
knockout [42,43] or MHC Class I deficient mice [44], did not
show an impact of this single intervention so a substantial effect
would not be expected. The impact of CD8
+ T cell depletion may
be substantially different in other mouse strains, such as BALB/c,
where the role of protective NK cells is less evident [43]. Studies
using novel immunoproteasome inhibitors [28], or using mutant
viruses which resist NK cells through deletion [45] or mutation in
M157 [46] may also provide insight into the impact of
immunoproteasome-dependent CD8
+ T cell populations on viral
load. Alternatively there may be important but subtle effects on
viral reactivation and latency as evidenced by experiments in the
susceptible BALB/c strain where single responses have been
deleted through viral mutation [47].
Notably responses to M38 and m139 are sustained or increase
over time compared to classical ‘‘memory’’ responses, a phenom-
enon described as memory ‘‘inflation’’. This feature was first
described in the BALB/c (susceptible) model [13,14], but
subsequently observed in the C57BL/6 (resistant) model [11]
using natural and transgenic epitopes. Re-exposure of such
‘‘inflating’’ populations to antigen over time appears to underlie
generation of these CD8
+ T cell pools [2], a hypothesis supported
by the ‘‘effector memory’’ phenotypic characteristics detectable in
the cell subsets [11,12]. One reason proposed why specific epitopes
attract ‘‘inflating’’ populations compared to others, is the
generation of peptides that escape the viral mechanisms for
downregulation of antigen processing. In particular, IE-1 derived
peptides might generate inflating populations since they are
generated early after infection [14]. However, this is not uniquely
the case as epitopes from later expressed proteins can also be
associated with inflation [13,32] and there are situations where
distinct peptides may be generated from the same protein (M38) in
which one epitope is inflating while the other is not [11]. We note
that the two inflating epitopes included in this study (M38 and
m139) had the least dependence on immunoproteasomes. We
speculate that this feature could contribute to their unique
immunologic profile. During chronic infection, in addition to the
constraints placed upon antigen presentation by viral gene
expression kinetics and immunoevasins, the ability to be presented
by cells low in LMP7 may provide an additional ‘‘filter’’ to limit
the number of inflating epitopes.
While the M38 CD8
+ T cell response does show inflation over
time, the m139 response, whilst still dominant, is maintained stably
and does not substantially further increase over time. This feature
has been noted previously in some MCMV responses [11]; some
responses are clearly maintained by antigen exposure (and thus do
not revert to ‘‘central’’ memory), but show long-term stability
rather than increase. In this case the overall size of the population
may be somewhat reduced compared to wild-type response due to
a limitation in antigen presentation, or alternatively by competi-
tion with newly arising responses.
The question of whether other novel CD8
+ T cell responses
arise is an important one. As a marker of overall T cell memory,
there was not a deficit in the proportion of splenic CD8
+ T cells
responding to PMA/Ionomycin through IFN-c secretion in LMP7
deficient mice at day 100 (data not shown). Thus it is possible that
responses outside those measured are entering the memory pool.
Further detailed analyses of novel specificities is required to define
any new responses, which may potentially normally be limited by
immunoproteasomes [19].
The responses analyzed in this paper remain functional, as
measured here by IFN-c secretion, although not all cells
demonstrated using tetramer staining were detectable in short
term functional assays (e.g. Fig 1). Overall, when this has been
extensively analyzed [11,12,14] these responses are both function-
Figure 5. Breadth of CD8
+ T cell responses to MCMV in LMP7
2/2 mice. A. Splenocytes were prepared from spleens of LMP7
2/2 and C57BL/6
control mice 7 days p.i. (n=5), pooled, and exposed to each of nineteen synthetic peptides corresponding to defined CD8 epitopes of MCMV (Table
S1), or media alone, in the presence of BFA for 5 hours. Splenocytes were subjected to CD8 surface stain, IFN-c ICCS and FACS analysis as for
Figure 1C. Frequency of IFN-c cells among CD8
+ T cells in infected C57BL/6 or LMP7
2/2 mice, 7 days p.i. is shown for each peptide. Data is shown
with background subtracted for both mouse strains, only for responses that in C57BL/6 mice were above background. Background is defined as three
times the sum of the mean and standard error of the mean response to stimulation with media control alone. B. A similar analysis was to that
described in Fig 5A was performed for CD8
+ T cell responses detectable at 100 days p.i. C. Example ICCS staining for C57BL/6 and LMP7
2/2 mice (day
100) in response to M45, m139 and M38 peptides.
doi:10.1371/journal.pone.0014646.g005
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protective, and in contrast to LCMV there is no evidence of
exhaustion. Given recent studies of the impact of LMP7 inhibition
on T cell derived IL-17 in tissue, it would be interesting to explore
this specific aspect in future in MCMV [48].
Combining the data we therefore propose a ‘‘2-cell’’ model for
the role of the immunoproteasome in MCMV (Figure 7). Under
normal circumstances in acute disease, antigen may be presented
or cross-presented on DCs and prime strong responses: since DCs
constitutively express immunoproteasomes, and the responses are
highly immunoproteasome dependent, a wide range of such
responses will be generated. Such responses are, however, unable
to protect infected cells against infection if these cells downregulate
LMP7. As infection is controlled, antigen production is limited by
a variety of factors, including NK cells, but in LMP7
lo cells, LMP7
dependent epitopes will not be re-presented and classical memory
Figure 6. CD8
+ T cell responses to M45 in LMP7
2/2 mice infected with M45-expressing rVV. A. Recombinant vaccinia viruses (rVVs) were
constructed containing foreign genes derived from the genomic sequence of MCMV Smith Strain (ATCC VR-194). Foreign genes were full length gene
encoding the MCMV protein M45 (M45-VV), or a ‘minigene’, encoding the antigenic fragment of M45 corresponding to the CD8 epitope M45 H-2
D
b9 8 5 HGIRNASFI
993 (M45 epitope-VV). Genes were designed for insertion between restriction sites for restriction endonucleases Apa I (59)a n dK p nI( 3 9). The
diagram shows recombinant genes and proteins encoded by the two rVVs used in this study: M45 VV encoding full-length M45; and M45 epitope-VV,
encoding the minimal D
b-restricted CD8 epitope of M45 only. B, C. LMP7
2/2 or C57BL/6 control mice were injected i.v. with 1610
6 pfu M45-VV (B), 1610
6 pfu
M45 epitope-VV(C)or anequivalent volume of PBS. Blood wassampled 7 daysp.i. bytail bleed. Peripheral blood lymphocytes were subjected to tetramer stain
with M45 D
b HGIRNSFI tetramer and FACS analysis as for Figure 1A. The frequency of cells specific for M45 H-2 D
b 985HGIRNASFI
993 among CD8
+ T cells in the
blood of MVacc and MGVacc - infected and mock-infected C57BL/6 and LMP7
2/2 mice, 7 days after infection, is shown.
doi:10.1371/journal.pone.0014646.g006
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will have the potential to be re-presented and from this limited
pool, ‘‘inflating’’ epitopes are selected. Since DCs are constitutive
expressors of LMP7, this suggests that the cells responsible for
antigen presentation during chronic infection could include other
APCs or infected cell populations. More generally, this data
suggests that DC-based strategies which prime CD8
+ T cell
responses in an immunoproteasome-rich environment may run
the risk of selecting CD8
+ T cell populations which are unable to
recognize target cells, in settings where a virus (or even tumor) has
modified its immunoproteasome cargo.
Overall our findings suggest that LMP7 and the immunoprotea-
some play a more significant role in MCMV than previously
suspected from studies of other virus infections. This may be
relevant to human HCMV infection and potentially infection with
other viruses which display comparable dynamics. To what extent
this situation has evolved to provide a viral advantage is not clear,
but the extent of the impact is very evident, and appears to be a
property of the viral sequence itself. These data can be added to the
renewed accumulation of interest in the impact of the immunopro-
teasome in infection and inflammation, following studies on LCMV
[28] and toxoplasma [49] (recently reviewed in Ref. [50]). Further
experiments to explore the role of the immunoproteasome in
herpesviral infections will be of great interest in the future.
Methods
Ethics statement: Mouse experiments were performed accord-
ing to UK Home Office regulations (project licence number PPL
30/2235) and after review and approval by the local ethical review
board at the University of Oxford.
Mice and viruses
C57BL/6 and LMP7
2/2 mice were bred in a specific pathogen
free animal facility unit at the John Radcliffe Hospital, University
of Oxford, United Kingdom. MCMV (Strain Smith, ATCC: VR-
194) was provided by Professor U.H. Koszinowski, Department of
Virology, Max von Pettenkofer Institute, Munich, Germany.
Vaccinia virus Western Reserve (VVWR, ATCC: VR-1354) was
used. Mice were injected intravenously (i.v.) with 1610
6 pfu
(100 ml) MCMV or rVV as indicated.
Peptides. Peptide stock solutions (1 mM) (Roswell Park
Memorial Institute media 1640 (RPMI; Sigma), di-methyl
sulfoxide (DMSO) (10%)) were stored at 280uC before use then
at 4uC for up to 2 months. DMSO concentrations in final cell
assays were less than 0.01%. Synthetic peptides with amino acid
sequences matching CD8
+ T cell epitopes from MCMV (Table
S1) were custom synthesized to 80–85% purity (Weatherall
Institute for Molecular Medicine peptide synthesis facility, John
Radcliffe Hospital, University of Oxford).
Staining protocols. R10 (RPMI-1640, foetal calf serum
(FCS) (10%), PSG (penicillin (5,000 U/ml) streptomycin (5 mg/
ml) and glutamine (5 mM)), b-mercaptoethanol (b-ME) (50 mM))
was used for temporary storage of lymphocytes after removal of
red blood cells (RBC) and of splenocytes before and during
preparation from whole spleens. FACSWash (PBS, FCS (2%),
EDTA (5 mM)) was used to suspend lymphocytes during staining
for FACS analysis. FACS Fix (phosphate buffered saline (PBS),
Para-formaldehyde (PFA) (1%)) was used to fix lymphocytes after
staining and prior to FACS analysis. Biotinylated MHC class I
molecules refolded with human b-2 microglobulin (b2M) and
peptide were stored in PBS at 280uC before use. Antibodies (Ab)
for fluorescence activated cell sorting (FACS) analysis included
CD8-PerCP or CD8-APC (Invitrogen). Intracellular stains used
IFN-c FITC after stimulation as previously described. All flow
cytometry was performed and analyzed using CellQuest3.3 or
FloJo acquisition software and FACScalibur flow cytometer (BD
Biosciences).
Generation of rVVs. MCMV M45 gene sequence data was
derived from NCBI sequence database, accession: ‘MuHV1_
gpM45’, NCBI GeneID: 3293809. Primers for amplification and
cloning of MCMV gene M45 were Forward primer: aagggc-
Figure 7. ‘‘2-cell’’ model to explain different effect of LMP7 on ‘‘inflating’’ memory and classical memory CD8
+ T cell responses to
MCMV. Infected or cross-presenting DCs during acute infection contain immunoproteasomes and constitutive proteasomes and stimulate responses
to epitopes produced by either proteasome. In chronic infection other APCs containing only constitutive proteasomes stimulate responses only to
those epitopes produced by the constitutive proteasome resulting in selection of more immunoproteasome-independent responses during chronic
infection.
doi:10.1371/journal.pone.0014646.g007
LMP7 and MCMV
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e14646ccaccATGGATCGCCAGCCCAAAGTC; Reverse primer: tag-
gtaccTCAGCGATAATTCACGGAAGGGG). BioX-Act Long
Mix (Bioline) was used for PCR. For the minigene, comple-
mentary oligo-nucleotides (oligos) were designed such that when
annealed they form a single short fragment of dsDNA or insert
encoding the amino acid sequence of the MHC class I epitope
M
985HGIRNASFI
993 (Sense strand: caccATGCACGGCATCA-
GGAACGCCTCCTTCATCTGAggtac; Antisense strand: cTC-
AGATGAAGGAGGCGTTCCTGATGCCGTGCATggtgggcc).
For cloning, Apa I, Kpn I, Sma I and Xmn I restriction enzymes
and T4 ligase were obtained from New England Biolabs (NEB).
Bacteria competent for transformation used in cloning were
TOP10 (Invitrogen), used for amplification of plasmids less than
12 kilobase pairs (kbp) in length or XL-1 Blue (Stratagene) used for
plasmids greater than 12 kbp.
All rVVs were prepared using previously described protocols
[34] and were confirmed by sequencing. For minigene recombi-
nants two primers were used: (Forward: CAAACCCACCC-
GCTTTTTAT; Reverse: TACGTTGAAATGTCCCATCG).
Sequencing full-length M45 gene required 16 additional primers
(Table S2). rVV prepared from viral plaques was subjected to
PCR using an ‘inside’ primer specific for a sequence unique to the
recombinant M45 full-length gene (GCGCCGCGGCCGCTC-
GGCG) or M45 D
b 985HGIRNASFI
993 minigene (GATGAAG-
GAGGCGTTCCTGATGCCGTGC) as appropriate. Sequence
Scanner (v1.0, Applied Biosystems) was used to determine quality
of sequence data. Sequence data was searched for mismatches
with published sequence using Clustal W (EMBL). Vaccinia
viruses were grown in thymidine kinase-negative human osteosar-
coma fibroblast cell line TK-143 (ATCC: CRL-8303).
Supporting Information
Table S1 Amino acid sequences of MCMV CD8+ T cell
epitopes referred to in this study.
Found at: doi:10.1371/journal.pone.0014646.s001 (0.11 MB
DOCX)
Table S2 Primers used for sequencing full-length gene M45.
Found at: doi:10.1371/journal.pone.0014646.s002 (0.12 MB
DOCX)
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